Updates

DOSE OF REALITY: BIG PHARMA CEOS FACE A RECKONING FROM LAWMAKERS AND EXPERTS ON ANTI-COMPETITIVE PRACTICES AND PRICE GOUGING

Feb 12, 2024

Patent Abuse Designed to Extend Monopolies, Block Competition and Keep Prices Read More

BIG PHARMA EARNINGS WATCH: PFIZER & GLAXOSMITHKLINE

Feb 9, 2024

Big Pharma Giants Continue Q4 Earnings Besting Wall Street Expectations Pfizer Read More

Advisory: Panel Discussion on Big Pharma’s Patent Abuse with CSRxP Executive Director Lauren Aronson

Feb 6, 2024

Lawmakers and Experts Will Discuss Solutions to Hold Big Pharma Accountable Read More

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Jan 31, 2024

Big Pharma Giant Kicks Off Q4 Earnings After Hiking Prices More Than 40 Times Read More

DOSE OF REALITY: BIG PHARMA’S EGREGIOUS PRICING PRACTICES AND ANTI-COMPETITIVE TACTICS DRIVE HIGHER HEALTH CARE COSTS

Jan 30, 2024

Big Pharma Price Hikes, Rising Launch Prices And Patent Abuse Impose Massive Read More

BIG PHARMA WATCH: AARP REPORT SHINES LIGHT ON SCALE AND COST OF BIG PHARMA’S PRICE HIKES THAT EXCEED INFLATION

Jan 19, 2024

Rx Price Watch Analysis Finds Big Pharma Price Increases Outpaced Inflation Read More

BIG PHARMA WATCH: BIG PHARMA DELAYS NEW DRUGS THAT COULD HELP PATIENTS TO BOOST PROFITS

Jan 8, 2024

Report Finds Several Brand Name Drug Companies Waiting to Introduce New Read More

CSRXP: GSK’S FLOVENT SCHEME DESIGNED TO SIDESTEP ACCOUNTABILITY FOR EGREGIOUS PRICE HIKES

Jan 5, 2024

Big Pharma Giant Switches Popular Brand Name Inhaler to Authorized Generic to Read More

DOSE OF REALITY: BIG PHARMA’S R&D INVESTMENTS DISCREDIT DOOM AND GLOOM INNOVATION RHETORIC

Jan 5, 2024

Report Finds Big Pharma Increased Spending on R&D in First Half of 2023, Read More

CSRXP: BIG PHARMA RINGS IN 2024 WITH EGREGIOUS PRICE HIKES ON HUNDREDS OF BRAND NAME PRESCRIPTION DRUGS

Jan 2, 2024

Big Pharma Maintains Business-as-Usual Approach to Price-Gouging Americans to Read More